{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:42:36Z","timestamp":1773456156808,"version":"3.50.1"},"reference-count":52,"publisher":"China Science Publishing & Media Ltd.","issue":"10","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770529"],"award-info":[{"award-number":["81770529"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700461"],"award-info":[{"award-number":["81700461"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015670","name":"Guangdong Gastrointestinal Disease Research Center","doi-asserted-by":"publisher","award":["2017B02029003"],"award-info":[{"award-number":["2017B02029003"]}],"id":[{"id":"10.13039\/501100015670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.1093\/abbs\/gmab107","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T11:08:12Z","timestamp":1627470492000},"page":"1290-1299","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Blockade of T helper 17 cell function ameliorates recurrent <italic>Clostridioides difficile<\/italic> infection in mice"],"prefix":"10.3724","volume":"53","author":[{"given":"Siqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y e","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P u","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"null","volume":"6","author":"Zhang T","year":"2016","unstructured":"Zhang T, Lin QY, Fei JX, Zhang Y, Lin MY, Jiang SH, Wang P. Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease. Sci Rep, 2016, 6:","journal-title":"Sci Rep"},{"key":"null","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","volume":"40","author":"Vardakas KZ","year":"2012","unstructured":"Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents, 2012, 40: 1-8.","journal-title":"Int J Antimicrob Agents"},{"key":"null","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","volume":"74","author":"Ghantoji SS","year":"2010","unstructured":"Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect, 2010, 74: 309-318.","journal-title":"J Hosp Infect"},{"key":"null","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1128\/JCM.02291-12","volume":"50","author":"Marsh JW","year":"2012","unstructured":"Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of relapse of Clostridium difficile disease with BI\/NAP1\/027. J Clin Microbiol, 2012, 50: 4078-4082.","journal-title":"J Clin Microbiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","volume":"58","author":"Recurrent JS","year":"2009","unstructured":"Recurrent JS. Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect, 2009, 58: 403-410.","journal-title":"J Infect"},{"key":"null","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2011.59","volume":"8","author":"Surawicz CM","year":"2011","unstructured":"Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol, 2011, 8: 330-339.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"null","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"Cohen SH","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol, 2010, 31: 431-455.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/526530","volume":"46","author":"Dubberke ER","year":"2008","unstructured":"Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis, 2008, 46: 497-4504.","journal-title":"Clin Infect Dis"},{"key":"null","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","volume":"66","author":"McDonald LC","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis, 2018, 66: 987-994.","journal-title":"Clin Infect Dis"},{"key":"null","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chest.2017.09.002","volume":"153","author":"Kelly BJ","year":"2018","unstructured":"Kelly BJ, Tebas P. Clinical practice and infrastructure review of fecal microbiota transplantation for Clostridium difficile infection. Chest, 2018, 153: 266-277.","journal-title":"Chest"},{"key":"null","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/clinids\/24.3.324","volume":"24","author":"Fekety R","year":"1997","unstructured":"Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis, 1997, 24: 324-333.","journal-title":"Clin Infect Dis"},{"key":"null","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.3748\/wjg.v16.i28.3573","volume":"16","author":"Kim JW","year":"2010","unstructured":"Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung HC. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol, 2010, 16: 3573-3577.","journal-title":"World J Gastroenterol"},{"key":"null","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30526-2","volume":"8","author":"Maria-Ferreira D","year":"2018","unstructured":"Maria-Ferreira D, Nascimento AM, Cipriani TR, Santana-Filho AP, Watanabe PDS, Sant Ana DMG, Luciano FB. Rhamnogalacturonan, a chemically-defined polysaccharide, improves intestinal barrier function in DSS-induced colitis in mice and human Caco-2 cells. Sci Rep, 2018, 8:","journal-title":"Sci Rep"},{"key":"null","volume":"6","author":"Zou Y","year":"2016","unstructured":"Zou Y, Lin J, Li W, Wu Z, He Z, Huang G, Wang J. Huangqin-tang ameliorates dextran sodium sulphate-induced colitis by regulating intestinal epithelial cell homeostasis, inflammation and immune response. Sci Rep, 2016, 6:","journal-title":"Sci Rep"},{"key":"null","volume":"8","author":"Zhou W","year":"2019","unstructured":"Zhou W, Yang Y, Mei C, Dong P, Mu S, Wu H, Zhou Y. Inhibition of Rho-kinase downregulates Th17 cells and ameliorates hepatic fibrosis by Schistosoma japonicum infection. Cells, 2019, 8:","journal-title":"Cells"},{"key":"null","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00394-019-02114-1","volume":"59","author":"Sharma A","year":"2020","unstructured":"Sharma A, Tirpude NV, Kulurkar PM, Sharma R, Padwad Y. Berberis lycium fruit extract attenuates oxi-inflammatory stress and promotes mucosal healing by mitigating NF-\u03baB\/c-Jun\/MAPKs signalling and augmenting splenic Treg proliferation in a murine model of dextran sulphate sodium-induced ulcerative colitis. Eur J Nutr, 2020, 59: 2663-2681.","journal-title":"Eur J Nutr"},{"key":"null","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.biopha.2019.01.001","volume":"111","author":"El-Akabawy G","year":"2019","unstructured":"El-Akabawy G, El-Sherif NM. Zeaxanthin exerts protective effects on acetic acid-induced colitis in rats via modulation of pro-inflammatory cytokines and oxidative stress. Biomed Pharmacother, 2019, 111: 841-851.","journal-title":"Biomed Pharmacother"},{"key":"null","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"Neurath MF","year":"2014","unstructured":"Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol, 2014, 14: 329-342.","journal-title":"Nat Rev Immunol"},{"key":"null","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ibd.20753","volume":"15","author":"Alex P","year":"2009","unstructured":"Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis, 2009, 15: 341-352.","journal-title":"Inflamm Bowel Dis"},{"key":"null","first-page":"00037","volume":"24","author":"Yu H","year":"2017","unstructured":"Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, Devaraj S. Cytokines are markers of the Clostridium difficile-induced inflammatory response and predict disease severity. Clin Vaccine Immunol, 2017, 24: 00037-17.","journal-title":"Clin Vaccine Immunol"},{"key":"null","volume":"9","author":"Deng H","year":"2018","unstructured":"Deng H, Yang S, Zhang Y, Qian K, Zhang Z, Liu Y, Wang Y. Bacteroides fragilis prevents Clostridium difficile infection in a mouse model by restoring gut barrier and microbiome regulation. Front Microbiol, 2018, 9:","journal-title":"Front Microbiol"},{"key":"null","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/ibd\/izx059","volume":"24","author":"Zhou F","year":"2018","unstructured":"Zhou F, Hamza T, Fleur AS, Zhang Y, Yu H, Chen K, Heath JE. Mice with inflammatory bowel disease are susceptible to Clostridium difficile infection with severe disease outcomes. Inflamm Bowel Dis, 2018, 24: 573-582.","journal-title":"Inflamm Bowel Dis"},{"key":"null","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1128\/IAI.01336-10","volume":"79","author":"Sun X","year":"2011","unstructured":"Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. Mouse relapse model of Clostridium difficile infection. Infect Immun, 2011, 79: 2856-2864.","journal-title":"Infect Immun"},{"key":"null","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1698-5","volume":"20","author":"Weng X","year":"2018","unstructured":"Weng X, Liu Y, Cui S, Cheng B. The role of ROR\u03b1 in salivary gland lesions in patients with primary Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther, 2018, 20:","journal-title":"Arthritis Res Ther"},{"key":"null","first-page":"01513","volume":"62","author":"Koon HW","year":"2017","unstructured":"Koon HW, Wang J, Mussatto CC, Ortiz C, Lee EC, Tran DH, Chen X. Fidaxomicin and OP-1118 inhibit Clostridium difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-\u03baB activity. Antimicrob Agents Chemother, 2017, 62: 01513-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"null","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/cas.12459","volume":"105","author":"Han Y","year":"2014","unstructured":"Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci, 2014, 105: 933-942.","journal-title":"Cancer Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jiph.2019.11.005","volume":"13","author":"Karaoui WR","year":"2020","unstructured":"Karaoui WR, Rustam LBO, Bou Daher H, Rimmani HH, Rasheed SS, Matar GM, Mahfouz R. Incidence, outcome, and risk factors for recurrence of nosocomial Clostridioides difficile infection in adults: a prospective cohort study. J Infect Public Health, 2020, 13: 485-490.","journal-title":"J Infect Public Health"},{"key":"null","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","volume":"38","author":"Czepiel J","year":"2019","unstructured":"Czepiel J, Dr\u00f3\u017cd\u017c M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis, 2019, 38: 1211-1221.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"null","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/cid\/cit147","volume":"56","author":"El Feghaly RE","year":"2013","unstructured":"El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis, 2013, 56: 1713-1721.","journal-title":"Clin Infect Dis"},{"key":"null","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.celrep.2016.06.007","volume":"16","author":"Buonomo EL","year":"2016","unstructured":"Buonomo EL, Cowardin CA, Wilson MG, Saleh MM, Pramoonjago P, Petri WA. Microbiota-regulated IL-25 increases eosinophil number to provide protection during Clostridium difficile infection. Cell Rep, 2016, 16: 432-443.","journal-title":"Cell Rep"},{"key":"null","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jamasurg.2018.3174","volume":"12","author":"Kulaylat AS","year":"2018","unstructured":"Kulaylat AS, Buonomo EL, Scully KW, Hollenbeak CS, Cook H, Petri WA, Stewart DB. Development and validation of a prediction model for mortality and adverse outcomes among patients with peripheral eosinopenia on admission for Clostridium difficile infection. JAMA Surg, 2018, 12: 1127-1133.","journal-title":"JAMA Surg"},{"key":"null","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10733-9","volume":"10","author":"Frisbee AL","year":"2019","unstructured":"Frisbee AL, Saleh MM, Young MK, Leslie JL, Simpson ME, Abhyankar MM, Cowardin CA. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. Nat Commun, 2019, 10:","journal-title":"Nat Commun"},{"key":"null","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2017.07.047","volume":"153","author":"Hegazy AN","year":"2017","unstructured":"Hegazy AN, West NR, Stubbington MJ, Wendt E, Suijker KI, Datsi A, This S. Circulating and tissue-resident CD4+ T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation. Gastroenterology, 2017, 153: 1320-1337.","journal-title":"Gastroenterology"},{"key":"null","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","volume":"140","author":"Littman DR","year":"2010","unstructured":"Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 2010, 140: 845-858.","journal-title":"Cell"},{"key":"null","doi-asserted-by":"crossref","first-page":"14033","DOI":"10.1074\/jbc.M400302200","volume":"279","author":"Kallen J","year":"2004","unstructured":"Kallen J, Schlaeppi JM, Bitsch F, Delhon I, Fournier B. Crystal structure of the human RORalpha ligand binding domain in complex with cholesterol sulfate at 2.2 A. J Biol Chem, 2004, 279: 14033-14038.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1074\/jbc.M109.080614","volume":"285","author":"Wang Y","year":"2010","unstructured":"Wang Y, Kumar N, Solt LA, Richardson TI, Helvering LM, Crumbley C, Garcia-Ordonez RD. Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. J Biol Chem, 2010, 285: 5013-5025.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.4049\/jimmunol.173.5.2952","volume":"173","author":"Dzhagalov I","year":"2004","unstructured":"Dzhagalov I, Gigu\u00e8re V, He YW. Lymphocyte development and function in the absence of retinoic acid-related orphan receptor alpha. J Immunol, 2004, 173: 2952-2959.","journal-title":"J Immunol"},{"key":"null","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.1992.tb09295.x","volume":"58","author":"Kopmels B","year":"1992","unstructured":"Kopmels B, Mariani J, Delhaye-Bouchaud N, Audibert F, Fradelizi D, Wollman EE. Evidence for a hyperexcitability state of staggerer mutant mice macrophages. J Neurochem, 1992, 58: 192-199.","journal-title":"J Neurochem"},{"key":"null","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/art.38272","volume":"66","author":"Chang MR","year":"2014","unstructured":"Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor \u03b3 is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol, 2014, 66: 579-588.","journal-title":"Arthritis Rheumatol"},{"key":"null","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd4100","volume":"13","author":"Kojetin DJ","year":"2014","unstructured":"Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov, 2014, 13: 197-216.","journal-title":"Nat Rev Drug Discov"},{"key":"null","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","volume":"472","author":"Solt LA","year":"2011","unstructured":"Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature, 2011, 472: 491-494.","journal-title":"Nature"},{"key":"null","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/cb1002762","volume":"6","author":"Kumar N","year":"2011","unstructured":"Kumar N, Kojetin DJ, Solt LA, Kumar KG, Nuhant P, Duckett DR, Cameron MD. Identification of SR3335 (ML-176): a synthetic ROR\u03b1 selective inverse agonist. ACS Chem Biol, 2011, 6: 218-222.","journal-title":"ACS Chem Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/cb100223d","volume":"5","author":"Wang Y","year":"2010","unstructured":"Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, Roush WR, Griffin PR. Identification of SR1078, a synthetic agonist for the orphan nuclear receptors ROR\u03b1 and ROR\u03b3. ACS Chem Biol, 2010, 5: 1029-1034.","journal-title":"ACS Chem Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.109.060905","volume":"77","author":"Kumar N","year":"2010","unstructured":"Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl.N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-\u03b1\/\u03b3 inverse agonist. Mol Pharmacol, 2010, 77: 228-236.","journal-title":"Mol Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/en.2014-1677","volume":"156","author":"Solt LA","year":"2015","unstructured":"Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes. Endocrinology, 2015, 156: 869-881.","journal-title":"Endocrinology"},{"key":"null","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1749-6632.2000.tb05263.x","volume":"915","author":"Pothoulakis C","year":"2000","unstructured":"Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann N Y Acad Sci, 2000, 915: 347-356.","journal-title":"Ann N Y Acad Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/gutjnl-2018-316818","volume":"67","author":"Mullish BH","year":"2018","unstructured":"Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 2018, 67: 1920-1941.","journal-title":"Gut"},{"key":"null","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.gastro.2011.11.037","volume":"142","author":"Mattila E","year":"2012","unstructured":"Mattila E, Uusitalo-Sepp\u00e4l\u00e4 R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, Moilanen V. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology, 2012, 142: 490-496.","journal-title":"Gastroenterology"},{"key":"null","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h6043","volume":"351","author":"Mullish BH","year":"2015","unstructured":"Mullish BH, Williams HR. Obstacles to establishing an NHS faecal transplant programme. BMJ, 2015, 351:","journal-title":"BMJ"},{"key":"null","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41564-019-0519-1","volume":"4","author":"Srikhanta YN","year":"2019","unstructured":"Srikhanta YN, Hutton ML, Awad MM, Drinkwater N, Singleton J, Day SL, Cunningham BA. Cephamycins inhibit pathogen sporulation and effectively treat recurrent Clostridioides difficile infection. Nat Microbiol, 2019, 4: 2237-2245.","journal-title":"Nat Microbiol"},{"key":"null","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-64882-9","volume":"10","author":"Abutaleb NS","year":"2020","unstructured":"Abutaleb NS, Seleem MN. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci Rep, 2020, 10:","journal-title":"Sci Rep"},{"key":"null","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1021\/acs.jmedchem.0c00123","volume":"63","author":"Blake S","year":"2020","unstructured":"Blake S, Thanissery R, Rivera AJ, Hixon MS, Lin M, Theriot CM, Janda KD. Salicylanilide analog minimizes relapse of Clostridioides difficile infection in mice. J Med Chem, 2020, 63: 6898-6908.","journal-title":"J Med Chem"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/BB20B089D3384C12BE8410782F86EBC1","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmab107","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/abbs\/article-pdf\/53\/10\/1290\/40575211\/gmab107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/BB20B089D3384C12BE8410782F86EBC1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T18:58:44Z","timestamp":1672945124000},"score":1,"resource":{"primary":{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmab107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,8,11]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abbs\/gmab107","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}